Share on StockTwits

Cynapsus Therapeutics (CVE:CTH) issued its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.02) by $0.02, StockRatingsNetwork reports.

Cynapsus Therapeutics Inc is a specialty pharmaceutical company developing non-injectable delivery of apomorphine to be used as a rescue therapy for off motor symptoms of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.